{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:23:49Z","timestamp":1790115829225,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T00:00:00Z","timestamp":1465862400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s12016-016-8560-9","type":"journal-article","created":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T03:55:13Z","timestamp":1465876513000},"page":"240-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: an Updated Meta-Analysis"],"prefix":"10.1007","volume":"51","author":[{"given":"Zheng-sheng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-ning","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,14]]},"reference":[{"key":"8560_CR1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00380-014-0490-y","volume":"30","author":"M Sunbul","year":"2015","unstructured":"Sunbul M, Seckin D, Durmus E, et al. (2015) Assessment of arterial stiffness and cardiovascular hemodynamics by oscillometric method in psoriasis patients with normal cardiac functions. Heart Vessel 30:347\u2013354","journal-title":"Heart Vessel"},{"key":"8560_CR2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/exd.12381","volume":"23","author":"S Gerdes","year":"2014","unstructured":"Gerdes S, Osadtschy S, Buhles N, et al. (2014) Cardiovascular biomarkers in patients with psoriasis. Exp Dermatol 23:322\u2013325","journal-title":"Exp Dermatol"},{"key":"8560_CR3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.atherosclerosis.2015.04.783","volume":"240","author":"R Khan","year":"2015","unstructured":"Khan R, Spagnoli V, Tardif JC, et al. (2015) Novel anti- inflammatory therapies for the treatment of atherosclerosis. Atherosclerosis 240:497\u2013509","journal-title":"Atherosclerosis"},{"key":"8560_CR4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2174\/13816128113199990712","volume":"20","author":"H Pieringer","year":"2014","unstructured":"Pieringer H, Pichler M, Pohanka E, et al. (2014) Will antirheumatic treatment improve cardiovascular outcomes in patients with rheumatoid arthritis? Curr Pharm Des 20:486\u2013495","journal-title":"Curr Pharm Des"},{"key":"8560_CR5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2013.09.020","volume":"70","author":"J Hugh","year":"2014","unstructured":"Hugh J, Van Voorhees AS, Nijhawan RI, et al. (2014) From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol 70:168\u2013177","journal-title":"J Am Acad Dermatol"},{"key":"8560_CR6","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/archdermatol.2012.2502","volume":"148","author":"JJ Wu","year":"2012","unstructured":"Wu JJ, Poon KY, Channual JC, et al. (2012) Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 148:1244\u20131250","journal-title":"Arch Dermatol"},{"key":"8560_CR7","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T, et al. (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74:480\u2013489","journal-title":"Ann Rheum Dis"},{"key":"8560_CR8","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2174\/138161282004140213123505","volume":"20","author":"AW Armstrong","year":"2014","unstructured":"Armstrong AW, Brezinski EA, Follansbee MR, et al. (2014) Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des 20:500\u2013512","journal-title":"Curr Pharm Des"},{"key":"8560_CR9","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, PRISMA Group, et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006\u20131012","journal-title":"J Clin Epidemiol"},{"key":"8560_CR10","unstructured":"Wells GSB, O\u2019Connel D. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analysisOttawa Hospital Research Institute Web site http:\/\/www.ohri.ca\/programs\/clinicalepidemiology\/oxford.asp"},{"key":"8560_CR11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N, et al. (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"8560_CR12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/9780470693926.ch15","volume-title":"Systematic reviews in health care: meta-analysis in context","author":"JJ Deeks","year":"2001","unstructured":"Deeks JJ, Altman DG, Bradburn MJ (2001) Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG (eds) Systematic reviews in health care: meta-analysis in context, 2nd edn. BMJ Publishing Group, London, pp. 285\u2013312","edition":"2nd"},{"key":"8560_CR13","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088\u20131101","journal-title":"Biometrics"},{"key":"8560_CR14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, et al. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"8560_CR15","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1365-2133.2011.10525.x","volume":"165","author":"K Abuabara","year":"2011","unstructured":"Abuabara K, Lee H, Kimball AB (2011) The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol 165:1066\u20131073","journal-title":"Br J Dermatol"},{"key":"8560_CR16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2796.2012.02593.x","volume":"273","author":"O Ahlehoff","year":"2013","unstructured":"Ahlehoff O, Skov L, Gislason G, et al. (2013) Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 273:197\u2013204","journal-title":"J Intern Med"},{"key":"8560_CR17","first-page":"899","volume":"12","author":"JJ Wu","year":"2013","unstructured":"Wu JJ, Poon KY, Bebchuk JD (2013) Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. J Drugs Dermatol 12:899\u2013903","journal-title":"J Drugs Dermatol"},{"key":"8560_CR18","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/jdv.12768","volume":"29","author":"O Ahlehoff","year":"2015","unstructured":"Ahlehoff O, Skov L, Gislason G, et al. (2015) Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol 29:1128\u20131134","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"8560_CR19","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.3899\/jrheum.090822","volume":"37","author":"AM Tobin","year":"2010","unstructured":"Tobin AM, Veale DJ, Fitzgerald O, et al. (2010) Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 37:1386\u20131394","journal-title":"J Rheumatol"},{"key":"8560_CR20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jdv.12163","volume":"27","author":"C Horreau","year":"2013","unstructured":"Horreau C, Pouplard C, Brenaut E, et al. (2013) Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol 27:12\u201329","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"8560_CR21","first-page":"932","volume":"13","author":"JJ Wu","year":"2014","unstructured":"Wu JJ, Poon KY (2014) Tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis, psoriatic arthritis, or both. J Drugs Dermatol 13:932\u2013934","journal-title":"J Drugs Dermatol"},{"key":"8560_CR22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM199007263230405","volume":"323","author":"B Levine","year":"1990","unstructured":"Levine B, Kalman J, Mayer L, et al. (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323:236\u2013241","journal-title":"N Engl J Med"},{"key":"8560_CR23","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/hc3501.096063","volume":"104","author":"T Kadokami","year":"2001","unstructured":"Kadokami T, Frye C, Lemster B, et al. (2001) Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation 104:1094\u20131097","journal-title":"Circulation"},{"key":"8560_CR24","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","volume":"109","author":"DL Mann","year":"2004","unstructured":"Mann DL, McMurray JJ, Packer M, et al. (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109:1594\u20131602","journal-title":"Circulation"},{"key":"8560_CR25","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung ES, Packer M, Lo KH, Anti-TNF Therapy Against Congestive Heart Failure Investigators, et al. (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133\u20133140","journal-title":"Circulation"},{"key":"8560_CR26","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1136\/annrheumdis-2012-202136","volume":"72","author":"DH Solomon","year":"2013","unstructured":"Solomon DH, Rassen JA, Kuriya B, et al. (2013) Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis 72:1813\u20131818","journal-title":"Ann Rheum Dis"},{"key":"8560_CR27","first-page":"864","volume":"306","author":"C Ryan","year":"2011","unstructured":"Ryan C, Leonardi CL, Krueger JG, et al. (2011) Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 306:864\u2013871","journal-title":"JAMA"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-016-8560-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-016-8560-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-016-8560-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T16:19:12Z","timestamp":1498321152000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-016-8560-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,14]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["8560"],"URL":"https:\/\/doi.org\/10.1007\/s12016-016-8560-9","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,14]]}}}